NorthStar Medical Radioisotopes is making organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business, the company announced today.

“NorthStar is now optimally positioned for continued growth and success in developing and delivering on our portfolio of medical radioisotopes to meet the needs of patients and advance clinical research,” NorthStar Medical Radioisotopes CEO Stephen Merrick said in a statement.

According to a release, the biotech company is developing and growing its strategic portfolio of specialized SPECT radiopharmaceuticals to meet increasing clinical needs for SPECT imaging. It is also applying its commercial-scale radioisotope production technology expertise to provide reliable Cu-67 and Ac-225 supply for use in advancing clinical research and for commercial radiopharmaceutical products.

Along with these changes, NorthStar appointed Dave Wilson, formerly VP of Commercial Operations, as VP of Advanced Radiopharmaceutical and Therapeutic Technologies.